Skip to main content
OpenTrials
Completed

NCT Number: NCT05648266

Serratus Plane Block After Minimally Invasive Mitral Valve Repair

Patients undergoing minimally invasive mitral valve reconstruction via small thoracotomy are randomized into two groups.

The intervention group receives serratus anterior plane block after minimally invasive mitral-valve reconstruction, following 48h infusion with ropivacaine 2% continually.

The control group receives a placebo pump without infusion. Primary endpoints are perceived pain using a numeric pain rating scale and opioid consumption during the hospital stay.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Minimal Invasive Cardiac Surgery Minimal Invasive Cardiac Surgery Mitral Valve Surgery Serratus Anterior Plane Block

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Hamburg Eppendorf

Hamburg, Free and Hanseatic City of Hamburg, 20251, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-Planned minimal invasive mitral valve repair via right anterior thoracotomy

Exclusion criteria

  • Pregenancy
  • Opioid abuse
  • Historyof chronic pain
  • Allergy to local anaesthetics (in this case ropivacain)
  • Patients who simultaneously participate in another interventional clinical trial, unless the Principal Investigators of the clinical trials give consent by mutual agreement Soft tissue infection in the area of the procedure

Treatment and study plan

Continous SAPB (Ropivacain)

Drug

postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h

institutional standard of care pain medication protocol

Other

institutional standard of care pain medication protocol

Primary outcomes

  1. Difference of Numeric Rating Scale after MIC-MKR

    Time frame: within 12, 24 and 48 hours after surgery

    Numeric Rating Scale (0-10, 0=smallest value, 10=greatest value)

Secondary outcomes

  1. Difference of opioid consumption after MIC-MVR

    Time frame: within 12, 24 and 48 hours after surgery

    daily, cumulative dose of opioid analgetic medication after MIC-MKR

Sponsors and collaborators

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf

Other

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Dec 13, 2022
Registry last updated
Oct 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.